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Abstract
BACKGROUND: The aim of this study was the assessment of utility of somatostatin receptor scintigraphy (SRS) by SPECT 
imaging using 99mTc-EDDA/HYNIC-Tyr3-octreotide (99mTc-EDDA/HYNIC-TOC) in patients with neuroendocrine neoplasm (NEN) 
or suspected NEN, referred to Nuclear Medicine Dept. of Voivodship Specialty Center in Rzeszow. The selected group of 
patients was referred also to 68Ga PET/CT. The posed question was the ratio of patients for whom PET/CT with 68Ga would 
change their management.
MATERIAL AND METHODS: The distribution of somatostatin receptors was imaged using 99mTc-EDDA/HYNIC-TOC in 61 planar 
and SPECT studies between 13/05/2010 and 04/02/2013 in Nuclear Medicine Dept. of Voivodship Specialty Center in Rzeszow. 
The patient age was within a range of 17–80, with the average age of 57.6. The average age of women (65% of patients over-
all) was 55.6 and the average age of men (35% of patients overall) was 61.4. In 46 participants (75% of the study group), that 
underwent SRS, NEN was documented using pathology tests. Selected patients were referred to PET/CT with 68Ga labeled 
somatostatin analogs, DOTATATE or DOTANOC. This study group consisted of 14 female and 10 male participants with age 
range of 35–77 and average age of 55.5 years. Patients were classified into 3 groups, as follows: detection — referral due to 
clinical symptoms and/or biochemical markers (CgA-Chromogranin A, IAA-indoleacetic acid) with the aim of primary diagnosis, 
staging — referral with the aim of assessment of tumor spread, and follow-up — assessment of the therapy.
RESULTS: Out of 61 patients, 24 underwent both 99mTc-EDDA/HYNIC-Tyr3-octreotide SPECT and 68Ga PET/CT. The result of 
PET/CT was used as a basis for further evaluation. Therefore, the patients were divided into groups; true positive TP (confirmed 
presence of tissue somatostatin receptors with 68Ga PET/CT) and TN (68Ga PET/CT did not detect any changes and the results 
were comparable and had the same influence on treatment protocol). In case of SPECT, the results were assigned as follows: 
TP, TN (in cases where the results were confirmed by 68Ga PET/CT), FP (patient’s scintigraphy demonstrated focal change by 
SPECT but not PET/CT) and FN (99mTc-EDDA/HYNIC-Tyr3-octreotide SPECT failed to demonstrate any abnormalities; however, 
the treatment protocol was changed after PET/CT).
CONCLUSIONS: The accuracy of SPECT diagnosis was found to be as high as 91.6%. Only in 8.4% of patients the additional 
PET/CT with 68Ga-labeled somatostatin analog changed the treatment protocol.
KEy words: somatostatin receptor imaging, SRS, SPECT, PET, 68Ga, 99mTc-EDDA/HyNIC-Tyr3-octreotide
Nucl Med Rev 2016; 19, 2: 88–92
89www.nmr.viamedica.pl
Dorota Mądrzak et al., Influence of PET/CT 68Ga somatostatin receptor imaging on proceeding with patients, who were previously diagnosed using 99mTc-Tektrotyd SPECT
Original
Introduction
Neuroendocrine neoplasms (NENs) are a heterogeneous group 
of diseases which are of epithelial origin. They are characterized by 
neuroendocrine differentiation. The incidence of NENs is estimated 
to be 4–5 cases per 100,000, which is 0.5% of all tumors [1] and 
is increasing. NEN can originate in any organ but most commonly 
(70% of all NEN) they form in the gastro-intestinal tract, so-called 
GEP-NEN (GastroEnteroPancreatic-NEN). About 30% of NENs lo-
calize in the respiratory tract. Over 50% of GEP-NENs are carcinoid 
tumors which are most commonly discovered during small bowel 
surgery, appendectomy or during staging process, involving mainly 
liver metastases [2]. They grow slowly and the time needed for the 
development of symptoms is long, which is the reason why this ill-
ness is usually diagnosed at an advanced stage. Nevertheless, 
patients have a long lifespan on average. Overall, 5 year survival 
rate is 67.2% [3].
NENs are visualized using conventional radiological methods, 
MRI, USG (ultrasonography), endoscopy, EUS (endoscopic ultra-
sonography) and nuclear medicine techniques. These diagnostic 
procedures are obligatory in the assessment of the tumor origin 
as well as in staging and follow-up. Currently, the nuclear medicine 
relies on methods based on SPECT and PET, commonly involving 
CT, which allows more precise tumor localization and attenuation 
correction [4]. The great majority of tumors are characterized 
by overexpression of somatostatin receptors (SSTRs) [1, 4–6]. 
Targeting of these receptors with radiolabeled somatostatin ana-
logs enabled the development of new imaging methods in vivo 
[7, 8]. 111In-pentetreotide (Octreoscan) was the first approved 
radiopharmaceutical for neuroendocrine tumor functional studies. 
Introduction of multi-head gamma cameras and tomographic acqui-
sition with SPECT allows for 3D imaging and increased sensitivity. 
Nevertheless, due to low resolution, any changes below 1 cm in 
diameter remain undiagnosed and also the long acquisition time 
required for 111In-pentetreotide have both spurred the search for new 
and improved imaging methods. The limitations of SPECT with 111In 
could be overcome with the development of 99mTc-labeled soma-
tostatin analogs, which caused wider interest in the use of these 
tracers for NEN imaging diagnostics. Availability of 99mTc obtained 
from radionuclide generators over 111In produced in cyclotrons im-
proved the accessibility of this diagnostic tool. Imaging with 99mTc 
enables the use of low-energy collimators with high resolution. The 
initial research on the use of 99mTc-EDDA/HYNIC-TOC has already 
demonstrated its advantage over 111In-pentetreotide for imaging of 
somatostatin receptor imaging [9]. Similar study was conducted 
also in Poland and showed the advantage of somatostatin receptor 
scintigraphy (SRS) with another 99mTc labeled somatostatin analog, 
99mTc-HYNIC-TATE over Octreoscan for the detection of primary le-
sion in patients with NEN [10], which was also supported by other 
research [11, 12]. In the last years patients with NEN are usually 
referred for SPECT with 99mTc-EDDA/HYNIC-Tyr3-octreotide (Tektro-
tyd), which was granted Marketing Authorization in Poland and in 
several other European countries for this indication. On the other 
hand, the better imaging properties of PET using 68Ga in combi-
nation with somatostatin analogs are based on the higher spatial 
resolution of this technique [13] but also need an optimal acquisi-
tion protocol. PET is a technique that utilizes radioisotopes that 
emit positrons — antielectrons. Positron-emitting radionuclide, 
which is introduced into the body on a biologically active molecule, 
emits positrons that upon contact with electrons annihilate produc-
ing two gamma rays, which are then detected by the PET scanner.
NENs are usually well differentiated and are characterized by 
overexpression of somatostatin receptors that can be targeted 
by synthetic somatostatin analogs. It has been fifteen years since 
Hoffman et al. [14] demonstrated the advantage of PET with 
somatostatin analog labeled with 68Ga (68Ga-DOTATOC) over 
111In-pentetreotide for detection of abdominal metastases, using 
tomography as a reference.
According to study by Gabriel et al. [15] who compared recep-
tor scintigraphy (111In-DOTATOC and 99mTc-EDDA/HYNIC-TOC) with 
PET (68Ga-DOTA-TOC) and CT in patients with NEN, PET showed 
diagnostic advantage over scintigraphy. In 38% cases there 
was a discrepancy between PET and scintigraphy, with PET show-
ing greater accuracy, which resulted in a change of treatment in 
14.3% of patients.
PET/CT diagnostics using somatostatin analogs with 68Ga are 
currently unavailable in Podkarpackie region. Nevertheless, due to 
the accessibility of SPECT, patients with NEN are usually referred 
for SPECT with 99mTc-EDDA/HYNIC-TOC (Tektrotyd). This diagnos-
tic procedure has been carried out in Nuclear Medicine Dept. of 
Voivodship Specialty Center in Rzeszow since 2010. At that time 
PET/CT using 68Ga radiolabeled somatostatin analogs was only 
available in a very few centers in Poland. 
The aim of this study was the comparative evaluation of the 
results of 99mTc-EDDA/HYNIC-TOC SPECT SRS, which was per-
formed in our Center, with the externally carried out PET/CT with 68Ga 
radiolabeled somatostatin analogs, and assessment of its influence 
on further diagnosis and treatment.
Material and methods
The distribution of somatostatin receptors was imaged using 
99mTc-EDDA/HYNIC-TOC in 61 planar and SPECT studies between 
13/05/2010 and 04/02/2013 in Nuclear Medicine Dept. of Voivodship 
Specialty Center in Rzeszow. 
 — study group age: 17–80;
 — average age: 57.6 yrs.;
 — female participants: 65%, average age 55.6 yrs.;
 — male participants: 35%, average age 61.4 yrs.
In 46 participants (75% of the study group), that underwent SRS, 
NEN was documented using pathomorphology tests.
However, the group of patients was referred to PET/CT with 
68Ga labeled somatostatin analog. It was not advised to patients for 
whom any more precise diagnosis would change a treatment 
protocol. For example, patient with tumor dissemination, whose 
scintigraphy result is shown in Figure 1, was not referred to further 
diagnosis even in the event of other metastases. Also, some pa-
tients refused to travel outside of Podkarpackie region.
Among a group of patients who were referred for SPECT, 24 pa-
tients had the PET/CT scans carried out. The diagnostic results of 
the above-mentioned patients were carefully analyzed, since they 
undergone both imaging procedures. The PET/CT was done be-
tween 3–16 weeks after SPECT scan. The study group consisted 
of 14 female and 10 male participants with age range of 35–77 and 
average age of 55.5 years.
Patients were classified into 3 groups, as follows:
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1. detection — referral due to clinical symptoms and/or bioche-
mical markers (CgA, IAA) with the aim of primary diagnostics — 
2 patients;
2. staging — referral with the aim of assessment of tumor spread, 
patients were diagnosed with NEN based on histopathology 
and oligobiopsy tests — 20 patients;
3. follow-up — assessment of the therapy — 2 patients.
Imaging was carried out with: Dualhead Gamma Camera 
e-CAM, manufactured by Siemens in 2006, equipped with LEAP co-
llimator. Imaging whole-type: 12 cm/s, Imaging SPECT-type: energy 
window 140 keV, width 10%, detector rotation 180°, 64 projections, 
128 x 128 matrix, 30 s/projection. Data was reconstructed based 
on iterative reconstruction.
99mTc-EDDA/HYNIC-Tyr3-octreotide (99mTc-Tektrotyd, National 
Centre for Nuclear Research, Polatom, Poland) was prepared ac-
cording to manufacturer instructions and administered in the dose 
of average radioactivity of 690–760 MBq, while 68Ga-DOTATATE and 
68Ga-DOTANOC were prepared in collaborating groups in Warsaw, 
Cracow and Gliwice according to the in-house developed protocols. 
Results
Out of 61 patients, 24 underwent both SPECT and 68Ga PET/CT. 
The result of PET/CT was used as a basis for further treatment. 
Therefore, the participants were divided into groups; true positive 
TP (confirmed presence of tissue somatostatin receptors with 68Ga 
PET/CT) and TN (68Ga PET/CT did not detect any changes and the 
results were comparable and had the same influence on treatment 
protocol).
In case of SPECT, the results were assigned as follows: TP, 
TN (in cases where the results were confirmed by 68Ga PET/CT), 
FP (patient’s scintigraphy demonstrated focal change by SPECT 
but not PET/CT) and FN (99mTc SPECT failed to demonstrate any 
abnormalities; however, the treatment protocol was changed after 
PET/CT). The results are presented in Table 1.
Based on data in Table 1, the accuracy of diagnosis using 
SPECT was calculated as follows:
ACCURACY = TP + TN / TP + TN + FP + FN = 11 + 11 / 11 + 11+ 
1 + 1 = 22/24 = 0.916; 91.6% 
100% – 91.6% = 8.4%
Hence, the accuracy of SPECT diagnosis is 91.6%. Only in 
8.4% of patients PET/CT with 68Ga labeled somatostatin ana-
logs changed the treatment protocol.
The clinical data, pertaining to two patients, whose treatment 
protocol was changed after PET/CT, is shown in Table 2.
Patient 1 was a 54-year-old male, who underwent middle lung 
lobectomy due to NEN in 2010. His blood test showed increased 
CgA and SPECT study indicated abnormal focal tracer concen-
Figure 1. SRS imaging of a patient with disseminated NEN — an example
Table 1. The results of assessing the influence of SPECT and 68Ga PET/CT on further patient treatment
SPECT PET/CT
GROUP N TP TN FP FN TP TN FP FN
Detection 2 0 2 0 0 0 2 0 0
Staging 20 11 8 1 0 11 9 0 0
Follow-up 2 0 1 0 1 1 1 0 0
Total 24 11 11 1 1 12 12 0 0
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trating in left suprarenal gland. However, PET/CT scan confirmed 
a physiological character of that focal change and as a result patient 
did not undergo surgery.
Patient 2 was a 67-year-old female, who underwent right 
hemicolectomy due to NEN and also suffered from suprarenal 
tumor based on CT scan. SPECT scan indicated abnormal tracer 
concentration in the affected suprarenal gland. However, PET/CT 
detected dissemination to mesentery lymph nodes, liver, bone and 
suprarenal glands. As a result, patient did not undergo adrenal-
ectomy but instead she was treated with somatostatin analogs.
Discussion
The aim of this prospective study was to assess the suit-
ability of dual-head gamma camera for diagnosis, staging and 
therapy monitoring of NEN by SRS SPECT. This study was carried 
out in Nuclear Medicine Dept. of Voivodship Specialty Center in 
Rzeszow from 09.2010 to 02.2013 and was continued thereafter. In 
this voivodship, somatostatin receptor scintigraphy was performed 
only sporadically until 2010 and PET/CT is still unavailable.
This study compares suitability of PET and SPECT methods in 
diagnosis and treatment assessment of NEN. Similar studies were 
carried out previously by Gabriel et al. [15]. They assessed 84 
patients, who were divided into groups: detection — 13 patients, 
staging — 36 patients and follow-up — 35 patients. They were diag-
nosed by PET using 68Ga-DOTATOC and SPECT with both 111In-DO-
TATOC and 99mTc-EDDA/HYNIC-TOC. According to this study, the 
discrepancy between SPECT and PET results was 38%, which 
influenced treatment protocol for 14.3% of patients [15]. The dis-
crepancy between the outcomes of the aforementioned research 
and our study (14.3% vs 8.4%) can be explained by the fact that 
Gabriel et al. [15] in 40% of patients directed for somatostatin recep-
tor scintigraphy used 111In-pentetreotide and the use of 2 different 
compounds for SRS SPECT has been a limitation in that study while 
in our patients we used 99mTc-EDDA/HYNIC-TOC only. In our study 
the calculated accuracy of diagnosis using SPECT 99mTc-Tektrotyd 
is 91.6%, which is due to the high sensitivity and specificity of 
this tracer. It is well in agreement with earlier SRS investigations us-
ing 99mTc-EDDA/HYNIC-TOC in GEP NET patients by Gabriel et al. 
[16] who reported the specificity of 80.9% and sensitivity 94.4% in 
the group of 88 patients, Gomez et al. [17] with the sensitivity of 87% 
and 100% specificity in 32 patients and Artiko et al. [18] with the 
sensitivity of 87% and specificity of 86% in the group of 30 patients, 
respectively. The treatment procedure was altered only for 8.4% of 
patients (2 persons) after PET/CT with 68Ga labeled somatostatin 
receptor agent. Hence, the reason for our results might be due to 
the use of 99mTc-Tektrotyd only. 
Table 2. Patients who benefited from PET/CT of somatostatin receptors imaging with 68Ga
No Sex Age Group Clinical presentation SPECT result PET result Change of treatment  
procedure after PET/CT
1 M 54 Staging Post middle lobectomy due to 
NEN in 2010, increased level 
of CgA
Focal abnormality in 
left adrenal gland FP
Physiological concentration in 
adrenal gland TN
Planned surgery abandoned
2 K 67 Follow-up Post right hemicolectomy due to 
NENG1; suprarenal gland tumor 
(CT)
Focal abnormality in 
left adrenal gland FN
Dissemination (metastasis to 
mesentery lymph nodes, liver, 
bone and suprarenal gland) TP
Planned surgery abandoned. 
Somatostatin analog therapy 
introduced
Some patients, who underwent SPECT in Voivodship Specialty 
Centre, were not diagnosed with PET, since the detection of ad-
ditional sites of disease by PET was not expected to influence the 
therapeutic approach [13, 19]. Theoretically, providing that other 
patients were included to the study, e.g. those who were diagnosed 
with NEN dissemination or those whose NEN was removed with safe 
margin, dissemination was negative in SRS and also the conven-
tional imaging (US, CT, MRI) did not indicate pathology, the PET/CT 
findings might not affect the patient’s clinical management. In such 
a case the calculated overall ratio of the patients who benefited from 
that test would be even lower. However, from this hypothetical cal-
culation a group of patients should be excluded who did not agree 
for the diagnostic tests outside of voivodship or who could not be 
transported further away due to overall poor health condition or those 
who were not diagnosed with NEN in pathomorphological tests.
Nevertheless, due to the small size of this study it is not con-
clusive and the results should be confirmed in a larger number of 
participants. The study is ongoing. 
Conclusions
This pilot study demonstrates high utility of somatostatin recep-
tor scintigraphy using 99mTc SPECT. The great majority of patients, 
who underwent both SPECT and 68Ga-PET/CT, were correctly 
diagnosed with SPECT only (91.6%). In the group under study, 
PET/CT changed the treatment protocol in only 8.4% of cases, out 
of 24 patients diagnosed with both techniques. 
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